CD40LG (CD40 ligand)

The small sample size and single arm design limits effect interpretation but the data shows promise for continued clinical investigation. Study registration: NCT04123470.

Moreover, BIM loss conferred broad resistance to chemotherapy and clinically relevant targeted agents. In contrast, treatment with bispecific T-cell engagers elicited robust cytotoxic responses regardless of BIM expression, underscoring the potential of immunotherapies to overcome TME-induced apoptotic resistance.

Moreover, lower levels of all miR-29s(a/b/c) were associated with shorter overall survival (OS) and progression-free survival in FL (n = 185), including in a multivariate analysis. Low miR-29c was also associated with shorter OS in a validation cohort (n = 92) from the first-line R-CHOP therapy clinical trial (SWOG S0016, NCT00006721).

UALCAN, The Human Protein Atlas(HPA), the Cancer Cell Line Encyclopedia(CCLE), TIMER, and TISIDB were used to analyze its relationship with clinical characteristics, co-expressed genes, immune infiltration, correlation with immunomodulators.GNPNAT1-associated gene, CD40LG was used to build a risk model to evaluate immunotherapy outcomes of patients with LUAD.GNPNAT1 was upregulated in LUAD both at mRNA and protein level in tumor tissues. Based on CD40LG, a risk model could predict the prognosis and immunotherapy outcome of LUAD.GNPNAT1 was an independent prognostic factor for LUAD.Our results have identified a prognosis-related gene that is useful to evaluate immunotherapy outcomes of LUAD patients.The signature may have crucial clinical significance in predicting survival prognosis, and immune infiltration based on GNPNAT1 gene.

Although hematopoietic stem cell transplantation remains curative for select IEIs, post-transplant malignancy risk persists. A deeper understanding of shared molecular pathways linking immunodeficiency and cancer is essential to refine early diagnosis, risk stratification, and targeted management in this vulnerable population.

Tnfsf15 homozygous knockout mice exhibited increased proteinuria and exacerbated glomerular injury compared with Tnfsf15(+/+) Alport mice during early disease. These findings support a protective role for Tnfsf15 in the early stages of Alport syndrome, mitigating proteinuria and limiting glomerular injury.

This study establishes a novel triple therapy that overcomes the limitations of BiTEs in cold and immunosuppressive TMEs and provides an immunomodulatory approach to addressing third-generation EGFR-TKI resistance.

sCD40L reference values differ by ELISA kit, underscoring the need for institution-specific reference ranges. Serum, not plasma, is preferable for sCD40L measurement. Establishing standardized reference ranges will improve the reliability of sCD40L as a biomarker in research fields.

DHMC acts as a novel natural chalcone that overcomes MDR via dual mechanisms, apoptosis induction and transporter inhibition, underscoring its importance as a potential adjuvant in cancer therapy.

Pathway analyses highlighted membrane-proximal processes (external plasma membrane and IgG binding) and a 16p11.2 signal. This integrative analysis identified CCR2-ARTN as a mechanistically supported immune-inflammation axis contributing to AML risk, offering a potential therapeutic target and warrants direct validation in primary CD62L + myeloid DCs.

P=N/A, N=330, Not yet recruiting, Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University

The significant increases in serum PDGF-AA and TGF-α, and significant decreases in serum EGF and Flt3 ligand could be explained by post-procedural inflammatory or paraneoplastic mechanisms. Further research into these biomarkers with larger cohorts may enable further understanding of their role pre- and post-operatively in TTPB and their correlation with clinical outcomes. This may be used to develop a clinical tool to predict or identify patients at risk of early post-TTPB complications.